Accendra Health (ACH) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 5% year-over-year to $2.7 billion, driven by strong demand in Patient Direct and Medical Distribution.

• Patient Direct segment saw robust growth, especially in diabetes and sleep supplies, while Products & Healthcare Services delivered mid-single-digit revenue growth.

• Nearly $200 million in total debt reduction achieved in Q3, including full redemption of 2024 senior notes, bringing year-to-date reduction to $210 million.

• Announced agreement to acquire Rotech Healthcare Holdings for $1.36 billion, expected to close in H1 2025, with fully committed financing.

• Operating income declined in Products & Healthcare Services but increased in Patient Direct for Q3 2024.

Financial highlights

• Q3 revenue was $2.7 billion, up 5% year-over-year; Patient Direct revenue: $687 million (+6%); Products & Healthcare Services revenue: $2.0 billion (+5%).

• Gross profit was $560 million (20.6% of net revenue), with margins up 20 bps sequentially but down 20 bps year-over-year due to prior LIFO credit.

• GAAP operating income was $24.2 million; adjusted operating income was $84.2 million, flat year-over-year and up 10% sequentially.

• Adjusted EBITDA was $142 million, up over 5% from Q3 2023.

• GAAP net loss was $12.8 million ($0.17/share); adjusted net income was $33.1 million ($0.42/share).

Outlook and guidance

• Full-year 2024 revenue expected between $10.6–$10.8 billion; adjusted EBITDA guidance set at $540–$550 million; adjusted EPS at $1.45–$1.55.

• Guidance excludes impact of Rotech acquisition.

• Gross margin anticipated between 20.5% and 21.0%; capital expenditures forecasted at $225–$235 million; interest expense projected at $142–$144 million.

• Expect sequential growth and improved cash flows in Q4 and into 2025.

• Outlook assumes stable commodity prices, current FX rates, and continued inflationary and pricing pressures.